FWP
IMDX

Flatrock Wealth Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Flatrock Wealth Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77K Hold
13,044
– – 0.03% 172
2026
Q1 		$42.8K Buy
+13,044
New +$75.7K 0.02% 165

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Flatrock Wealth Partners's IMDX Position: Q2 2026 in Review

Flatrock Wealth Partners held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 13,044 shares worth $77K. The position accounts for 0.03% of the portfolio, ranked #172.

Flatrock Wealth Partners first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Flatrock Wealth Partners held 13,044 shares of Insight Molecular Diagnostics worth $77K as of Q2 2026.
  • Flatrock Wealth Partners left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
  • Insight Molecular Diagnostics made up 0.03% of Flatrock Wealth Partners's portfolio in Q2 2026, its #172 holding.
  • Flatrock Wealth Partners first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Flatrock Wealth Partners's 13F filing for Q2 2026, filed 14 Aug 2026.